New Zealand markets open in 44 minutes

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
13.53-0.12 (-0.88%)
At close: 1:00PM EST
13.60 +0.07 (+0.52%)
After hours: 04:33PM EST
Full screen
Trade prices are not sourced from all markets
Previous close13.65
Bid13.56 x 1400
Ask13.52 x 3100
Day's range13.42 - 13.63
52-week range13.42 - 19.97
Avg. volume2,417,246
Market cap42.858B
Beta (5Y monthly)1.08
PE ratio (TTM)10.38
Earnings dateN/A
Forward dividend & yield0.84 (6.19%)
Ex-dividend date30 Mar 2021
1y target estN/A
  • Zacks

    Takeda (TAK) CMV Infection Drug Livtencity Gets FDA Approval

    The FDA grants approval to the new drug application seeking approval for Takeda's (TAK) maribavir for treating post-transplant cytomegalovirus infection.

  • Yahoo Finance

    Novavax asks for FDA meeting after first global authorization for COVID-19 vaccine: CEO

    Novavax (NVAX) is getting some momentum for its two-dose COVID-19 vaccine, starting with a series of emergency use fillings globally and the first authorization in Indonesia this month. The company is on track to file with the U.S. Food and Drug Administration (FDA) by the end of the year, and has already called for a meeting with the agency to move forward, according to CEO Stanley Erck. Erck told Yahoo Finance Live on Wednesday that the company expects to hear back from the FDA "very soon" and believes Novavax could receive up to five authorizations in the coming 6-8 weeks globally. But a majority of its distribution of actual doses is likely to start at the beginning of 2022.

  • Yahoo Finance

    Novavax files for its first COVID-19 vaccine authorization in UK

    Novavax CEO Stanley Erck discusses the company's first COVID-19 vaccine authorization filing, in the U.K., and how quickly other global filings are planned.